Natal’a Valer’evna Filippova

Natal’a Valer’evna Filippova

Auto-generated profile, based on publicly available information

Natal’a Valer’evna Filippova

V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, Saratov, Russia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2023 in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
Verified
Journal Article
Open access
PDF file
NFN. V. Filippova
N. V. Filippova
YBYu. B. Barylnik
Yu. B. Barylnik
TBT. M. Bogdanova
T. M. Bogdanova
VBV. V. Blinova
V. V. Blinova
ASA. A. Shchelchkova
A. A. Shchelchkova
EME. S. Mozgacheva
E. S. Mozgacheva
Importance of the problem. Diseases of the cardiovascular system are in the first place among the causes of death and disability in most industrialized countries, which is undoubtedly an urgent medical and social problem and causes significant economic damage. The prevalence of depressive disorders in modern society, according to WHO estimates, is quite high, and the causes of depressive disorders and methods for their correction in patients with various somatic diseases have been the subject of study by specialists around the world for many decades. The comorbidity of depressive disorders with cardiac pathology is beyond doubt, and the bidirectional relationship of these disorders significantly aggravates the condition of patients, worsens their quality of life and reduces adherence to treatment. The most important conditions for the use of antidepressants in cardiology practice are good tolerability, absence of toxic effect, minimal interaction with other drugs, and relative safety in case of overdose. Vortioxetine, being a modern multimodal antidepressant, demonstrates not only a sufficiently high antidepressant and anti-anxiety activity, but also has a procognitive effect, as well as minimal side effects and undesirable cross-interactions with other drugs, which is confirmed by international randomized placebo-controlled trials. The aim of this work was to evaluate the efficacy and safety of Vortioxetine in the treatment of concomitant depressive disorders in patients with coronary heart disease (CHD), angina pectoris 2-3 functional class (FC) (I 20.8 according to ICD-10), receiving complex therapy for the main (cardiological) diseases at the inpatient and outpatient stages of therapy. Materials and methods. The study included patients with a diagnosis of coronary artery disease, angina pectoris FC 2-3, hypertension 2-3, aged 45 to 66 years (mean age 57.1±1.1 years), receiving complex therapy for the underlying cardiac disease and Vortioxetine at a dose of 10-15 mg/day. within 8 weeks. Anxiety and depressive manifestations were assessed on the HADS scale, the level of cognitive impairment on the PDQ questionnaire, social functioning on the SF-36 questionnaire, the general clinical impression on the CGI-C scale, and the main indicators of the functioning of the cardiovascular system upon admission to the hospital, after 4 weeks of hospitalization. treatment and another 4 weeks after discharge during the period of outpatient observation.The result of the combined therapy of patients with cardiac pathology and concomitant depressive disorder (basic therapy for CVD and Vortioxetine) was not only an improvement in the cardiovascular system (decrease in heart rate, blood pressure, the frequency of anginal pain, an increase in exercise tolerance), but also the relief of depressive manifestations, which contributed to an increase in the adherence of cardiological patients to the implementation of medical recommendations, and, in turn, led to a decrease in the level of end points—mortality, hospitalization rates, progression of chronic heart failure and disability. Conclusions. Appointment of Vortioxetine to cardiac patients with concomitant depressive disorder of moderate severity is quite effective not only in terms of relief of painful manifestations of the CVS, but also leads to a reduction in anxiety-depressive disorders and an improvement in cognitive and social functioning. The good tolerability of the drug makes it possible to recommend it for the treatment of depressive disorders in cardiological patients in a hospital setting and in outpatient practice.

27 August 2021 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
EIElena Sergeevna Ilyina
Elena Sergeevna Ilyina
NFNatal’a Valer’evna Filippova
Natal’a Valer’evna Filippova
YBYulia Borisovna Barylnik
Yulia Borisovna Barylnik
Pharmacogenetics is a relatively new scientific discipline, which is currently the main tool in personalized medicine. The aim of research in this area is to identify significant genetic markers for the introduction of their accounting in routine clinical practice. Generalization of data on the patient’s phenotype should be the key to predicting the pharmacokinetics and pharmacodynamics of the drug in the body. A personalized approach based on pharmacogenetic research data in psychiatry is extremely relevant due to the high social and budgetary costs of treating mental disorders around the world. Currently, there are data on the pharmacogenetics of most modern antidepressants, however, conducting such studies in patients with depressive disorders in most cases is impossible for implementation in routine clinical practice due to the impossibility of conducting the test in the laboratory of medical organizations and the lack of specialists competent in the clinical interpretation of the results of pharmacogenetic testing.

15 October 2025 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
SSSaratov Shi «Regional Clinical Psychiatric Hospital Of Saint Sophia»
Saratov Shi «Regional Clinical Psychiatric Hospital Of Saint Sophia»
PBP. P. Bychkova
P. P. Bychkova
NFN. V. Filippova
N. V. Filippova
YBYu. B. Barylnik
Yu. B. Barylnik
A cross-sectional online study analyzed data from 145 pediatricians who completed a sociodemographic questionnaire and the Russian-adapted version of the KCAHW (Knowledge about Childhood Autism among Health Workers) scale. Knowledge levels were assessed using quartile distribution, with Q3=68.1 % set as the threshold for adequate awareness. Logistic regression analysis revealed that 59.3 % of respondents had completed continuing medical education courses in child and adolescent psychiatry (CAP), 60.7 % had reviewed relevant medical literature, and 49.7 % attended specialized training sessions. The highest accuracy rates were observed in the «social interaction» domain (Q1=89.5 %), while the lowest scores concerned «neurodevelopmental aspects.» Significant predictors of suboptimal performance (<Q3) included unmarried status (OR=3.60) and lack of clinical CAP experience (OR=8.49). These findings highlight the need for enhanced specialized training to improve ASD recognition in primary care.

16 June 2022 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
NFNatal’a Valer’evna Filippova
Natal’a Valer’evna Filippova
SAShakhla Tofig Kyzy Azimova
Shakhla Tofig Kyzy Azimova
RARashad Ragif Ogly Aliev
Rashad Ragif Ogly Aliev
In many parts of the world, alcohol use, especially among young people, is a growing concern. Excessive alcohol consumption has a negative impact on various social aspects of life, social well-being and economic development in general, leading to the development of a range of mental and physical diseases, as well as causing injuries from road traffic accidents, suicide attempts and acts of violence. The results of an anonymous survey among students of the Saratov State Medical University named after V.I. Razumovsky of the Ministry of Health of Russia showed that despite sufficient awareness of the dangers of alcohol, young people continue to drink alcoholic beverages. This fact confirms the need for state regulation of alcohol consumption at the national and global levels. The harmful effects of alcohol consumption among young people can be reduced through the use of proven technologies and strategies for the prevention of alcohol dependence on the part of the state and society.

25 March 2023 in Vestnik Nevrologii, Psihiatrii i Nejrohirurgii (Bulletin of Neurology, Psychiatry and Neurosurgery)
Verified
Journal Article
Closed access
NFN. V. Filippova
N. V. Filippova
YBYu. B. Barylnik
Yu. B. Barylnik
TBT. M. Bogdanova
T. M. Bogdanova
ASA. A. Shchelchkova
A. A. Shchelchkova
EME. S. Mozgacheva
E. S. Mozgacheva
The prevalence of depressive disorders in modern society is quite high, which is an important medical and social issue throughout the world. The role of psychosocial factors in the development of cardiovascular diseases, as well as the high comorbidity of cardiac pathology and depression in recent decades, are beyond doubt. Therapy for depressive disorders in cardiac patients should combine efficacy and safety, as well as ensure patient adherence to therapy. Despite the rather large number and wide availability of antidepressants, including those that are relatively safe in relation to the treatment of depression in cardiovascular pathology, there is a need to search for new depressive disorders treatment options that are even safer and more effective, especially in patients with various comorbid pathologies and concomitant therapy.

14 May 2026 in SibScript
Verified
Journal Article
Closed access
NFNatalia V. Filippova
Natalia V. Filippova
TLTatyana Yu. Ledvanova
Tatyana Yu. Ledvanova
AAAnastasia A. Antonova
Anastasia A. Antonova
YBYulia B. Barylnik
Yulia B. Barylnik
While psychological defenses, coping strategies, and anticipatory consistency are typically studied in isolation, this fragmentation creates a theoretical gap in understanding their systemic interaction as a unified mechanism of adaptation. This study addresses this limitation by proposing an original integrative functionalhierarchical model. The model defines a three-tier hierarchy: psychological defenses (basal level), coping strategies (intermediate level), and anticipatory competence (highest level). These components are linked through a dynamic system of principles, including compensation, hierarchical regulation, and dynamic equilibrium. By emphasizing the mechanism of compensation, the model resolves the long-standing contradiction between the neurobiological structural overlap and the functional hierarchy. Based on a methodology that spans comparative theoretical analysis, neuroscience, and cross-cultural developmental data, the review examines how adaptation disorders (rigidity, dissociation, and deficits) reveal specific neural correlates and socio-cultural variations. This new framework provides comprehensive diagnostics by identifying patterns of imbalance. Furthermore, it enables differentiated psychological interventions across multiple levels, marking a significant advancement in the study of neuroplasticity and systemic adaptation.